Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 30;26(4):579–593. doi: 10.1038/s41593-023-01284-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023, corrected publication 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a, Experimental setup for LFP recording with in vivo pharmacology. b, Example cortical LFP data following i.p. injections of either saline (black) or the Adra1a-specific agonist A61603 (1 µg kg⁻¹, red). c, Representative spectrograms from saline-injected (top) and A61603 -injected (bottom) mice. Arrows and vertical lines indicate time of injection. d, Left: example of 2–7 Hz band power change with saline or A61603 injection, smoothed with a 2 min moving average. Right: A61603 increased LF power compared with saline (two-sided signed-rank test, n = 10 mice). e, Left: representative trace of 70–100 Hz band power with saline or A61603 injection. Right: A61603 did not affect HF power compared with saline (two-sided signed-rank test, n = 10 mice). f, LFP recordings were performed in homozygous Adra1a^fl/fl mice and wild-type littermate controls; all mice were injected with GFAP-Cre. g, Representative 30 s of LFP data from Adra1a^fl/fl (green) and wild-type (black) mice. h, Average LFP spectra from Adra1a^fl/fl (n = 5) and wild-type (n = 9) mice, with total LFP power higher in Adra1a^fl/fl mice (two-sided t-test, shaded region shows theoretical error bars with P = 0.05). i, Average LFP spectrograms around movement offset (t = 0 s) for wild-type (left) and Adra1a^fl/fl (right) mice. Data are normalized by the median power at each frequency to show state-related changes in LFP. Top: entire spectrograms from 0–100 Hz. Middle: 70–100 Hz range showing increased power in Adra1a^fl/fl mice compared with wild type during movement. Bottom: 2–7 Hz range showing reduced power after movement offset in Adra1a^fl/fl mice. j, There was increased 70–100 Hz power in Adra1a^fl/fl mice during movement (left, n = 303 wild-type and 194 Adra1a^fl/fl movement offsets) between cohorts (right, n = 5 Adra1a^fl/fl and 9 wild-type mice, two-sided t-test). k, Same as in j for 2–7 Hz power after mice stopped moving. For all scatter plots, individual data are plotted as mean ± s.e.m.